Seoul Economic Daily EnglishCodex · 实盘不做把握 6/10
北京时间·🕒 发布 06:59:40时区推断·⟳ 抓取 08:21:15·⚡ 决策 07-23 08:33:46 +12m31s·96.4 天前
三星生物制剂二季度营收1.3209万亿韩元、营业利润5864亿韩元
二季度收入同比增30.2%至1.3209万亿韩元，营业利润同比增22.9%至5864亿韩元。
📄 原文Seoul Economic Daily English↗ 原文
Samsung Biologics Q2 Operating Profit Rises 22.9% to 586.4 Billion Won
Samsung Biologics (207940.KS) reported second-quarter revenue of 1.3209 trillion won and operating profit of 586.4 bill…
不做 Samsung Biologics（207940.KS）
财报同比增长明确但缺少相对一致预期的正向surprise，且股价已当日反应，不做。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
🔎 新鲜度:最早出现 2026-07-23 · 扩散 high · price-in 风险 medium ↗
消息传播链
- 公司监管文件披露二季度收入1.3209万亿韩元、营业利润5864亿韩元。市场反应:207940.KS截至2026-07-23 00:30 UTC上涨1.60%。
关键理由
- 二季度收入同比增30.2%至1.3209万亿韩元，营业利润同比增22.9%至5864亿韩元。
- 增长来自1至4号工厂满产和汇率利好，但原文未给相对一致预期的超预期幅度。
主要风险
- 财报类事件默认需要验证超预期，且207940.KS市值约433亿韩元口径下体量较大，单季同比增长不足以直接判定短线重定价空间。
反向证据
- 做多前查反向 · 来源 kb_search · 影响 weakens
内部KB未命中可用的一致预期差额；无法证明财报显著超预期。
检索:Samsung Biologics Q2 2026 operating profit 586.4 billion consensus
工具调用 · 历史记录,结果未知(4 种)
- stock_quote · 结果未知
- normalize_ticker · 结果未知
- search_processed_events · 结果未知
- kb_search · 结果未知
原文全文
展开原文 · 691 字
Samsung Biologics (207940.KS) reported second-quarter revenue of 1.3209 trillion won and operating profit of 586.4 billion won, the company said in a regulatory filing on the 23rd.
Revenue increased by 306.7 billion won, or 30.2%, from the same period a year earlier, while operating profit rose 109.2 billion won, or 22.9%.
Samsung Biologics said it sustained solid growth on the back of full operation of its Plants 1 through 4 and favorable exchange rate effects. Its operating profit margin remained in the 40% range, even as related costs were recognized in advance ahead of the full-scale revenue recognition from Plant 5 and its production facility in Rockville, in the United States.
Revenue increased by 306.7 billion won, or 30.2%, from the same period a year earlier, while operating profit rose 109.2 billion won, or 22.9%.
Samsung Biologics said it sustained solid growth on the back of full operation of its Plants 1 through 4 and favorable exchange rate effects. Its operating profit margin remained in the 40% range, even as related costs were recognized in advance ahead of the full-scale revenue recognition from Plant 5 and its production facility in Rockville, in the United States.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。